Nurix Therapeutics Inc NRIX

$25.34 -0.17 (-0.67%)

Valuation

Market cap
2,786,968,000
Revenue TTM
$83,980,000
Net income TTM
$-264,460,000
PE ratio
11.26
Forward PE
22.80
Profit margin
-314.91%
Debt to equity
0.00

Trading

Volume
1,910,400
Avg volume
1,790,004
Day's range
$24.77 – $25.49
Shares out
109,250,000
Stochastic %K
80%
Beta
1.82
Analysts
Strong Sell
Price target
$34.50

Price

Company profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and auto...

Show more

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 660 5320
Website
https://www.nurixtx.com
Address
1600 Sierra Point Parkway, Brisbane, United States

Latest news

Stocktwits

shoc24 Oct 23, 8:46 PM
$NRIX Fresh healthcare-sector scores for today from stockmeadow.com. NRIX ranks number 1 in my balanced healthcare model.
0 replies
resistancebreakers Oct 20, 7:17 PM
$NRIX squeeze and chill is better than $NFLX and chill 😉🪖🫡☝️
0 replies
kimvicki541 Oct 16, 12:47 AM
$NRIX
0 replies
resistancebreakers Oct 15, 6:09 PM
$NRIX still cheap just like $NUTX 🫶🪖🫡☝️
0 replies
topstockalerts Oct 14, 11:04 PM
$NRIX this is actually holding up way better than I thought
0 replies
Ravbcentinal Oct 14, 5:00 PM
$NRIX better better cover!
1 replies
resistancebreakers Oct 13, 5:11 PM
$NRIX undervalued! It crushed earnings yesterday - 24% short interest 🔥🪖🫡☝️
0 replies
KryptonResearch14 Oct 13, 4:33 PM
$NRIX Nurix printed a profit, which is not really the business yet. Fiscal Q3 revenue was 673.1 million dollars, but 653.2 million of it was one license recognition from the Roche collaboration. Collaboration revenue itself was 19.9 million, a bit below the 21.5 million analysts expected (MT Newswires). Diluted EPS was 4.73 vs a 1.03 loss a year ago, and cash is now 1.1 billion dollars, runway into the second half of 2029 per the company. The Roche money funds the pipeline. It does not change what the recurring revenue looks like.
0 replies